Genmab reported DKK9.89B in Cash and Equivalent for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Agios Pharmaceuticals AGIO:US USD 139.26M 16.81M
Amarin AMRN:US USD 240.5M 12.5M
Amgen AMGN:US USD 9.3B 197M
Artemis Alpha ATS:LN GBP 2.39M 4.76M
AstraZeneca AZN:LN USD 6.17B 1.71B
Bayer BAYN:GR EUR 5.17B 810M
Biomarin Pharmaceutical BMRN:US USD 724.53M 36.98M
Bluebird Bio BLUE:US USD 66.48M 15.02M
Exelixis EXEL:US USD 501.2M 174.09M
Fresenius Medical Care FME:GR EUR 1.27B 160.23M
Genmab GEN:DC DKK 9.89B 484M
GlaxoSmithKline GSK:LN GBP 3.72B 117M
GN Store Nord GN:DC DKK 990M 120M
Hikma Pharmaceutical HIK:LN USD 1000K 22M
Immunogen IMGN:US USD 275.14M 34.37M
Insmed INSM:US USD 1.07B 659.4M
Lonza Group LONN:SW CHF 1.34B 187M
Merck MRK:GR EUR 1.85B 250M
Novartis NOVN:VX USD 7.52B 1.21B
Regeneron Pharmaceuticals REGN:US USD 14.33B 10.84B
Roche Holding ROG:VX 4.99B 676M
Seattle Genetics SGEN:US USD 319.94M 42.66M